However, more recently, the approval of targeted therapies with EGFR or VEGF antibodies has importantly improved the overall survival, approaching 30 months in clinical trials [262], but the relative unavailability of biomarkers in metastatic CRC has slowed the progress in tumor curacy. This evidence concerns the gene VEGFA and neoplasm.